Key facts
- This page summarizes Arjun Agarwal's Form 4 filing for Oruka Therapeutics, Inc. (ORKA).
- 9 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 14 Aug 2026, 17:42.
Arjun Agarwal - 13 Aug 2026 Form 4 Insider Report for Oruka Therapeutics, Inc. (ORKA)
- Reporting relationship
- Senior Vice President, Finance
- Issuer ticker
- ORKA
- Reported as of
- 13 Aug 2026
- Net transaction value
- -$1,066,572
- SEC form
- 4
- Accepted by SEC
- 14 Aug 2026, 17:42:56 UTC
- Prior SEC filing
- 13 Jul 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Paul Quinlan, as attorney-in-fact for Arjun Agarwal
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Arjun Agarwal filed Form 4 for Oruka Therapeutics, Inc. (ORKA) on 14 Aug 2026.
Change
- Previous filing in this sequence was filed on 13 Jul 2026.
- Current net transaction value: -$1,066,572.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002033974
Primary reporting owner
Agarwal Arjun
- Relationship
- Senior Vice President, Finance
- Address
- C/O ORUKA THERAPEUTICS, INC., 855 OAK GROVE AVE., SUITE 100, MENLO PARK
- Signature
- /s/ Paul Quinlan, as attorney-in-fact for Arjun Agarwal
- Signature date
- 14 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ORKA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +8,542
- Change %
- +56%
- Price
- $12.50*
- Shares after
- 23,854
- Date
- 13 Aug 2026
- Ownership
- Direct
ORKA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +1,458
- Change %
- +6.1%
- Price
- $34.39*
- Shares after
- 25,312
- Date
- 13 Aug 2026
- Ownership
- Direct
ORKA
transaction
Common Stock
Sale
- Transaction value
- $219,814
- Shares
- -2,100
- Change %
- -8.3%
- Price
- $104.67
- Shares after
- 23,212
- Date
- 13 Aug 2026
- Ownership
- Direct
- Footnotes
- F1, F2
ORKA
transaction
Common Stock
Sale
- Transaction value
- $225,079
- Shares
- -2,132
- Change %
- -9.2%
- Price
- $105.57
- Shares after
- 21,080
- Date
- 13 Aug 2026
- Ownership
- Direct
- Footnotes
- F1, F3
ORKA
transaction
Common Stock
Sale
- Transaction value
- $135,201
- Shares
- -1,268
- Change %
- -6%
- Price
- $106.63
- Shares after
- 19,812
- Date
- 13 Aug 2026
- Ownership
- Direct
- Footnotes
- F1, F4
ORKA
transaction
Common Stock
Sale
- Transaction value
- $230,723
- Shares
- -2,142
- Change %
- -11%
- Price
- $107.71
- Shares after
- 17,670
- Date
- 13 Aug 2026
- Ownership
- Direct
- Footnotes
- F1, F5
ORKA
transaction
Common Stock
Sale
- Transaction value
- $255,755
- Shares
- -2,358
- Change %
- -13%
- Price
- $108.46
- Shares after
- 15,312
- Date
- 13 Aug 2026
- Ownership
- Direct
- Footnotes
- F1, F6
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ORKA
transaction
Derivative
Employee Stock Option (right to buy)
Options Exercise
- Transaction value
- Shares
- -8,542
- Change %
- -8.4%
- Price
- $0.000000*
- Shares after
- 92,917
- Date
- 13 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,542
- Exercise price
- $12.50
- Footnotes
- F7
ORKA
transaction
Derivative
Employee Stock Option (right to buy)
Options Exercise
- Transaction value
- Shares
- -1,458
- Change %
- -2.4%
- Price
- $0.000000*
- Shares after
- 59,792
- Date
- 13 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,458
- Exercise price
- $34.39
- Footnotes
- F8
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 8 footnotes
Footnote F1
These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.05 to $104.99, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.11 to $106.08, inclusive.
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.11 to $107.07, inclusive.
Footnote F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.20 to $108.19, inclusive.
Footnote F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.24 to $108.71, inclusive.
Footnote F7
The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.
Footnote F8
The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.